Posted inCardiology Clinical Updates news
Continued versus Discontinued Oral Anticoagulant Therapy for Unprovoked Venous Thromboembolism: A Target Trial Emulation and Evidence Synthesis
Continued oral anticoagulant therapy after ≥90 days for unprovoked VTE significantly lowers recurrence and mortality despite increased bleeding risk, offering a net clinical benefit consistent across anticoagulant types and treatment durations.
